Company’s 36-month beta value is 1.49.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EYPT is 61.98M, and currently, short sellers hold a 15.19% ratio of that floaft. The average trading volume of EYPT on December 27, 2024 was 908.04K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EYPT) stock’s latest price update
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has seen a decline in its stock price by -3.25 in relation to its previous close of 7.58. However, the company has experienced a 3.00% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-16 that WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EYPT’s Market Performance
EYPT’s stock has risen by 3.00% in the past week, with a monthly drop of -18.52% and a quarterly drop of -8.10%. The volatility ratio for the week is 6.76% while the volatility levels for the last 30 days are 6.61% for EyePoint Pharmaceuticals Inc The simple moving average for the last 20 days is -7.80% for EYPT stock, with a simple moving average of -35.18% for the last 200 days.
Analysts’ Opinion of EYPT
Jefferies, on the other hand, stated in their research note that they expect to see EYPT reach a price target of $15. The rating they have provided for EYPT stocks is “Buy” according to the report published on August 28th, 2024.
JP Morgan gave a rating of “Overweight” to EYPT, setting the target price at $35 in the report published on January 22nd of the current year.
EYPT Trading at -22.67% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.34% of loss for the given period.
Volatility was left at 6.61%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares sank -17.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.87% lower at present.
During the last 5 trading sessions, EYPT rose by +4.78%, which changed the moving average for the period of 200-days by -66.23% in comparison to the 20-day moving average, which settled at $7.96. In addition, EyePoint Pharmaceuticals Inc saw -68.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from ANTHONY P. ADAMIS, who proposed sale 67,100 shares at the price of $10.04 back on Oct 23 ’24. After this action, ANTHONY P. ADAMIS now owns shares of EyePoint Pharmaceuticals Inc, valued at $673,355 using the latest closing price.
David R. Guyer, the Former Director of EyePoint Pharmaceuticals Inc, proposed sale 36,975 shares at $8.92 during a trade that took place back on Oct 14 ’24, which means that David R. Guyer is holding shares at $329,817 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -2.56 for the present operating margin
- 0.91 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -2.27. The total capital return value is set at -0.46. Equity return is now at value -74.68, with -44.94 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.18.
Currently, EBITDA for the company is -69.0 million with net debt to EBITDA at 0.55. When we switch over and look at the enterprise to sales, we see a ratio of 9.81. The receivables turnover for the company is 120.93for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.50.
Conclusion
In a nutshell, EyePoint Pharmaceuticals Inc (EYPT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
